2021年最新SCI期刊影响因子查询系统
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 期刊详细信息
基本信息
期刊名称 | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS |
---|---|
期刊ISSN | 1080-7683 |
期刊官方网站 | http://www.liebertpub.com/overview/journal-of-ocular-pharmacology-and-therapeutics/40/ |
是否OA | 否 |
出版商 | Mary Ann Liebert Inc. |
出版周期 | Quarterly |
始发年份 | 1995 |
年文章数 | 72 |
最新影响因子 | 2.85(2021) |
中科院SCI期刊分区
大类学科 | 小类学科 | Top | 综述 |
---|---|---|---|
医学4区 | OPHTHALMOLOGY 眼科学4区 | 否 | 否 |
PHARMACOLOGY & PHARMACY 药学4区 |
CiteScore
CiteScore排名 | CiteScore | SJR | SNIP | ||
---|---|---|---|---|---|
学科 | 排名 | 百分位 | 1.73 | 0.658 | 0.697 |
Medicine Ophthalmology |
35 / 110 | 68% |
|||
Medicine Pharmacology (medical) |
115 / 232 | 50% |
|||
Pharmacology, Toxicology and Pharmaceutics Pharmacology |
172 / 300 | 42% |
补充信息
自引率 | 6.70% |
---|---|
H-index | 49 |
SCI收录状况 |
Science Citation Index Expanded |
官方审稿时间 | |
网友分享审稿时间 | 数据统计中,敬请期待。 |
PubMed Central (PML) | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1080-7683%5BISSN%5D |
投稿指南
期刊投稿网址 | http://www.liebertpub.com/overview/journal-of-ocular-pharmacology-and-therapeutics/40/ |
---|---|
收稿范围 | Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders. Journal of Ocular Pharmacology and Therapeutics coverage includes: Glaucoma Cataracts Retinal degeneration Ocular infection, trauma, and toxicology Ocular drug delivery and biotransformation Ocular pharmacotherapy/clinical trials Ocular inflammatory and immune disorders Gene and cell-based therapies Ocular metabolic disorders Ocular ischemia and blood flow Proliferative disorders of the eye Eyes on Drug Discovery - written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA Journal of Ocular Pharmacology and Therapeutics is under the editorial leadership of W. Daniel Stamer, PhD, Duke University; and his Associate Editors: Uday Kompella, PhD, University of Colorado Denver, Drug Delivery; Michael Niesman, PhD, MingSight Pharmaceuticals, Retinal Pharmacology; Naj A. Sharif, PhD, FARVO, Santen Incorporated, Pre-clinical Ocular Pharmacology; Linda D. Hazlett, PhD, Wayne State University School of Medicine, Ocular Surface Pharmacology; Carol B. Toris, PhD, University of Nebraska Medical Center, Aqueous Humor Dynamics; and an editorial board of leading experts. Audience: Academic, industry, and government scientists, ophthalmologists, optometrists, clinical and research trainees, and many others |
收录体裁 | |
投稿指南 | |
投稿模板 | |
参考文献格式 | |
编辑信息 |